XML 40 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Disaggregation of Revenues and Concentration Risk (Tables)
3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Consolidated Revenues Generated by Unaffiliated Customers

The following table presents the percentage of consolidated revenues generated by unaffiliated customers that individually represent greater than ten percent of consolidated revenues:

 

   

Three Months Ended

March 31,

 
    2021     2020  
Medicare for DetermaRx™     27%       -%  
Medicare Advantage for DetermaRx™     27%       -  
Pharma Services Company A     20%       *  
Pharma Services Company B     15%       *  
Schedule of Consolidated Revenues Attributable to Products or Services

The following table presents the percentage of consolidated revenues attributable to products or services classes that represent greater than ten percent of consolidated revenues:

 

   

Three Months Ended

March 31,

 
    2021     2020  
DetermaRx™     54%       10%  
Pharma Services     46%       90%  
Total     100%       100%  
Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations

The following table presents the percentage of consolidated revenues attributable to geographical locations:

 

   

Three Months Ended

March 31,

 
    2021     2020  
United States     57%       95%  
Outside of the United States – Pharma Services     43%       5%  
Total     100%       100%  
Schedule of Percentage of Total Consolidated Accounts Receivables

The following table presents accounts receivable, as a percentage of total consolidated accounts receivables, from third-party payers and other customers that provided in excess of 10% of Oncocyte’s total accounts receivable.

 

    March 31, 2021     December 31, 2020  
Pharma Services Company A     24%       35%  
Medicare for DetermaRx™     16%       45%  
Pharma Services Company B     18%       -  
Medicare Advantage for DetermaRx™     38%       -